DMD #11429
Introduction N G -nitro-arginine (NNA) is an inhibitor of nitric oxide synthase, exhibiting stereospecificity such that the L-but not the D-enantiomer inhibits nitric oxide synthesis in vitro (Moncada et al., 1991; Wang et al., 1999) . However, in vivo administration of the inactive D-enantiomer (D-NNA) produced the same biological effects as its L-enantiomer (L-NNA), such as raising blood pressure that was blocked by administration of L-arginine but not D-arginine (Wang et al., 1991 (Wang et al., , 1993 , leading to a notion that D-NNA was converted into L-NNA in vivo (Wang et al., 1993) . Wang et al (1999) from another laboratory demonstrated that D-NNA was indeed unidirectionally converted into L-NNA in vivo by using chiral HPLC. Furthermore, the kidney was confirmed to be the major organ accounting for approximately 80% of chiral inversion of D-NNA in vivo (Xin et al., 2005) .
It was hypothesized that D-NNA unidirectionally converts to L-NNA by a two-step pathway involving the oxidation of D-NNA to N G -nitro-5-gunidino-2-oxopentanoic acid by D-amino acid oxidase (DAAO) followed by amination to L-NNA by an unidentified transaminase (Wang et al., 1999; Xin et al., 2006) . Several lines of evidence support the above hypothesis.
(1) DAAO incubation with D-NNA in vitro reduced D-NNA content (Wang et al., 1999) ; (2) the chiral inversion rate of D-NNA was parallel with the DAAO activity in tissues homogenates (Xin et al, 2005) ; (3) injection of the inhibitor of DAAO benzoate completely blocked the pressor response to naive DMD #11429 determined according to the 'keto acid method ' (D'Aniello et al., 1996; Sarower et al., 2003) . 
Pharmacokinetics studies Conscious rats were divided into four groups
This article has not been copyedited and formatted. The final version may differ from this version. (n = 5 in each group). Two groups of rats were injected with D-NNA (32 mg/kg) or L-NNA (16 mg/kg), respectively. The other two groups of rats were pretreated with injection of sodium benzoate (400 mg/kg), a selective inhibitor of DAAO and effectively blocks DAAO activity at this dose (Moses et al., 1996; Xin et al., 2005 Xin et al., , 2006 . 
Pharmacokinetics Analyses
Pharmacokinetics parameters were obtained from the plasma concentration-time curves using non-compartmental model. Data was weighted 1/c 2 . The elimination half-life (T 1/2 ) was calculated by 0.693/K el . The chiral inversion rate of D-NNA to L-NNA was calculated using the following formula (Pang and Kwan, 1993) :
The area under the curve (AUC) was calculated by the trapezoidal rule. 
Data Analyses

Results and Discussion
Previous findings suggested that chiral inversion of D-NNA was metabolized by kidney DAAO (Wang et al., 1999; Xin et al., 2005 Xin et al., , 2006 .
However, further experiments such as those using DAAO inhibitors are needed to confirm the above hypothesis. Sodium benzoate was selected as a DAAO inhibitor for this study to examine whether DAAO inhibitors block chiral inversion of D-NNA in vitro and in vivo.
Our previous study indicated that D-NNA but not L-NNA was the substrate of DAAO and the K cat /K m of DAAO to D-NNA was about 10% of that to D-alanine, the optimum substrate for kidney DAAO (Xin et al., 2006) . In kidney homogenates, DAAO activity was measured by using 'keto acid method' where 0.1 M D-alanine was used (D'Aniello et al., 1996; Sarower et al., 2003) .
Sodium benzoate inhibited DAAO activity in a sigmoid concentration-response manner ( Fig. 1) , with the IC 50 value of 6.7 mM (95% confidence interval, 5.72 to 7.68 mM). Our results, together with a previous report that the K d for benzoate to inhibit DAAO was approximately 0.2 mM (Pilone, 2000) , suggest that benzoate is a weak inhibitor of DAAO. Moreover, the chiral inversion of D-NNA in this study was observed at 50 mM D-NNA, in contrast to the measurement of DAAO activity where 0.1 M D-alanine was used. Benzoate also blocked the chiral inversion of D-NNA in kidney homogenates, with the concentration-response curve correlating very well to that of the inhibition of DAAO activity (Fig. 1) Pharmacokinetics of D-NNA was studied in two groups of conscious rats (n = 5 in each group) pretreated with the vehicle or benzoate. I.V. bolus injection of D-NNA (32 mg/kg) exhibited a biphasic disposition curve while D-NNA was almost undetectable in plasma after 3 hours of administration ( Fig. 2A) , with calculated CL and T 1/2 of 0.98 ± 0.07 L/h/kg and 0.55 ± 0.33 h, respectively (Table 1) . Meanwhile L-NNA was immediately detected in the plasma following D-NNA injection and the plasma concentration of L-NNA exceeded that of D-NNA at 1.5 hours and reached the peak at 2 hours after D-NNA dosage ( Fig. 2A) . In order to observe whether inhibition of the DAAO activity blocked the chiral inversion of D-NNA in vivo, conscious rats were pretreated with benzoate at 400 mg/kg, a dosage selected based on the biological effects of D-dopa (Moses et al., 1996) , as well as results from a previous study that showed benzoate led to the inhibition of DAAO activity (Williams and Lock, (Table 1 ). Table 1 (London and Gabel, 1988) .
In order to find out whether the effect of benzoate on pharmacokinetics of D-NNA was specific on chiral inversion blockade, the effect of benzoate on L-NNA pharmacokinetics was tested in two groups of conscious rats (n = 5 in each group). I.V. bolus injection of L-NNA (16 mg/kg) also exhibited a biphasic disposition curve in control rats (Fig. 3A,) , with calculated CL and T 1/2 of 0.19 L/hr/kg and 5.21 hours, respectively (Table 1) . These parameters clearly showed a stereoselectivity in pharmacokinetics of NNA in which CL and T 1/2 of L-NNA had approximately 5-fold and 10-fold differences from those of D-NNA ( stereoselective disposition of NNA in anesthetized rats (Wang et al., 1999) .
Unlike in D-NNA injection, in which L-NNA was immediately detected, the D-enantiomer of L-NNA was not detected in plasma samples during the period observed after L-NNA administration, confirming that chiral inversion of D-NNA was unidirectional (Wang et al., 1999) . On the other hand, benzoate pretreatment, as shown in Fig 3B, did not significantly affect pharmacokinetic parameters of L-NNA (Table 1) , excluding the possibility that the effect of benzoate on D-NNA chiral inversion and clearance was non-specific.
Moreover, in the presence of benzoate for complete blockade of chiral inversion, the difference in pharmacokinetics parameters between D-NNA and L-NNA became significantly smaller (only approximately 2 folds) ( Table 1 ). The results suggest that chiral inversion mostly contributes to clearance stereoselectivity of NNA.
According to the 'Pang and Kwan formula ' (1993) , the calculated inversion rate of D-NNA to L-NNA was 36.7 ± 0.6%. Chiral inversion ratio of D-NNA to L-NNA calculated from this study was in agreement with the potency ratio (40%) of L-NNA/D-NNA to increase blood pressure in conscious rats (Wang et al., 1991) , as well as chiral inversion of D-NNA in anesthetized rats (Wang et al., 1999) .
It is well known that most chiral drugs exhibit stereospecificity in their pharmacokinetics. Enantioselectivity of pharmacokinetics may be influenced by enzymatic metabolism, carrier transport, protein binding, distribution, and
This article has not been copyedited and formatted. The final version may differ from this version. elimination of different stereoisomers (Burke et al., 2002) . In this study, we suggest that chiral inversion is an additional factor which contributes to pharmacokinetics stereospecificity, particularly in clearance. It was recently reported that many chiral pharmaceuticals undergo chiral inversion in vivo, such as certain D-amino acids (Hasegawa et al., 2000; Lehmann et al., 1983) , 2-arylpropionic acid analogs (Drummond et al., 1990) , the new quinoxaline toposomerase poison 2-[4-(7-chloro-2-quinoxaliny)oxy] phenoxy propionic acid (Zheng et al., 2002) , and thalidomide (Eriksson et al., 1998) . Therefore, chiral inversion may be an important contributing factor for pharmacokinetics stereospecificity of these chiral drugs.
In summary, D-NNA and L-NNA in conscious rats exhibited biphasic disposition in conscious rats with different pharmacokinetics parameters.
Unidirectional chiral inversion of D-NNA but not L-NNA was found in animals.
In Tables   Table 1 Pharmacokinetic parameters All readings are mean ± S.E.M.
